Bernd Metzner, PhD, a director of Anavex®, is currently Chief Financial Officer of the Stroeer Group.  Previously, he was Chief Administration Officer and member of the Board of Management of Bayer Schering Pharma AG, the pharmaceutical division of $100+ billion market cap company Bayer AG.  In this position, Dr. Metzner had worldwide financial responsibility for the Bayer Pharma Group.  During his almost 10-years with Bayer AG, Dr. Metzner also held several senior international management positions in the corporate finance organization of Bayer AG, including Chief Financial Officer of Bayer S.p.A. Italy and heading the coordination of the successful spin-off of Lanxess, a specialty chemicals group.  Dr. Metzner started his career at the law firm Flick Gocke Schaumburg and has a degree in business administration from the University of Siegen.  After obtaining his doctorate, he became a chartered accountant. Bernd Metzner, PhD, a director of Anavex®, is currently Chief Financial Officer of the Stroeer Group.  Previously, he was Chief Administration Officer and member of the Board of Management of Bayer Schering Pharma AG, the pharmaceutical division of $100+ billion market cap company Bayer AG.  In this position, Dr. Metzner had worldwide financial responsibility for the Bayer Pharma Group.  During his almost 10-years with Bayer AG, Dr. Metzner also held several senior international management positions in the corporate finance organization of Bayer AG, including Chief Financial Officer of Bayer S.p.A. Italy and heading the coordination of the successful spin-off of Lanxess, a specialty chemicals group.  Dr. Metzner started his career at the law firm Flick Gocke Schaumburg and has a degree in business administration from the University of Siegen.  After obtaining his doctorate, he became a chartered accountant.

Biotechnology